Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01634061 · ClinicalTrials.gov registry record · Phase 1
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01634061 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 43 participants.
The verdict
NCT01634061, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is an open label study of abiraterone acetate in combination with BEZ235 and abiraterone acetate in combination with BKM120 in CRPC patients with abiraterone acetate failure.
Interventions
- DRUG BEZ235
- DRUG BKM120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01634061
The ClinicalTrials.gov registry entry for NCT01634061 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BEZ235 is the first listed.
NCT01634061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01634061 about?
NCT01634061 is a clinical study titled "Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients". This is an open label study of abiraterone acetate in combination with BEZ235 and abiraterone acetate in combination with BKM120 in CRPC patients with abiraterone acetate failure.
What is the current status of trial NCT01634061?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2012-09. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01634061?
The interventions under investigation include: BEZ235 (DRUG), BKM120 (DRUG).
Who is sponsoring clinical trial NCT01634061?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.